Abstract:<p>Patients with Glycogen Storage Disease type 1a (GSD Ia) primarily present with life-threatening hypoglycemia and display severe liver disease characterized by hepatomegaly. Despite strict dietary management, long-term complications still occur, amongst which liver tumor development. Variations in residual glucose-6-phosphatase (G6PC1) activity likely contribute to phenotypic heterogeneity in biochemical symptoms and complications between patients. However, lack of insight into the relationship between G6PC1 activity and symptoms/complications, and poor understanding of the underlying disease mechanisms pose major challenges to provide optimal healthcare and quality of life for GSD Ia patients. Currently available GSD Ia animal models are not suitable to systematically investigate the relationship between hepatic G6PC activity and phenotypic heterogeneity, or the contribution of gene-gene interactions in the liver. To meet these needs, we generated and characterized a novel hepatocyte-specific GSD Ia mouse model using somatic CRISPR/Cas9-mediated gene editing. Hepatic <i>G6pc</i> editing reduced hepatic G6PC activity up to 98% and resulted in failure to thrive, fasting hypoglycemia, hypertriglyceridemia, hepatomegaly, hepatic steatosis, and increased liver tumor incidence. This approach was furthermore successful to simultaneously modulate hepatic G6PC and ChREBP, a transcription factor that is activated in GSD Ia and protects against hepatic steatosis under these conditions. Importantly, it also allowed to model a spectrum of GSD Ia phenotypes in terms of hepatic G6PC activity, fasting hypoglycemia, hypertriglyceridemia, hepatomegaly and hepatic steatosis. In conclusion, we show that somatic CRISPR/Cas9-mediated gene editing allows to model a spectrum of hepatocyte-borne GSD Ia disease symptoms in mice, and to efficiently study gene-gene interactions in the liver. This approach opens new perspectives for translational research and will likely contribute to novel and personalized treatments for GSD Ia and other genetic liver diseases.</p>

A Genetic Model of Substrate Deprivation Therapy for a Glycosphingolipid Storage Disorder.

Reactivation of mTOR signaling slows neurodegeneration in a lysosomal sphingolipid storage disease

MFSD12 affects glycosphingolipid metabolism by modulating lysosome homeostasis

Lysosomal storage results in impaired survival but normal neurite outgrowth in dorsal root ganglion neurones from a mouse model of Sandhoff disease

A Xenograft and Cell Line Model of SDH-deficient Pheochromocytoma Derived from Sdhb+/− Rats

Neuronal Ganglioside and Glycosphingolipid (GSL) Metabolism and Disease : Cascades of Secondary Metabolic Errors Can Generate Complex Pathologies (in LSDs)

Iminosugars for the treatment of lysosomal storage disorders

Natural history study of hepatic glycogen storage disease type IV and comparison to Gbe1ys/ys model

Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors As Substrate Reduction Therapy for Gaucher Disease Type 3.

Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease

A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a in mice with G6PC c.648G>T

Characterization of early markers of disease in the mouse model of mucopolysaccharidosis IIIB

Gene Therapy for Glycogen Storage Diseases

Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor

Plasma Membrane Remodelling in GM2 Gangliosidoses Drives Synaptic Dysfunction

Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells

Rare Diseases in Glycosphingolipid Metabolism

mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease

Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis

Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR‐associated protein 9–Mediated Gene Editing

Decreasing ganglioside synthesis delays motor and cognitive symptom onset in knockout mice